Compare Crown Castle International Corp (CCI) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs GSK plc — how do they compare? Crown Castle International Corp trades at $73.76 (market cap $31.33B), while GSK plc trades at $50.33 (market cap $102.60B). The key difference: GSK plc is far larger — about 3.3× Crown Castle International Corp's market cap, and Crown Castle International Corp pays the higher dividend (5.77%). Which is the better fit depends on your goals.
| CCI | GSK | |
|---|---|---|
Market Cap | $31.33B | $102.60B |
Sector | Real Estate | Health |
52-Week High | $103.79 | $61.18 |
52-Week Low | $73.61 | $38.22 |
Enterprise Value | $53.69B | $123.04B |
Dividend Yield | 5.77% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $73.98, near 52-week lows, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 AFFO of $1.13 per share, beating estimates, and raised full-year guidance amid its transition to a pure-play U.S. tower operator. Revenue declined to $4.26B in 2025 but profitability improved with 20.72% net margin. Analyst consensus remains divided with 50% buy ratings and $95.29 price target suggesting 29% upside.
The stock presents a value opportunity with discounted valuation and 5.5% dividend yield, but faces headwinds from high debt levels (77.21% debt-to-asset ratio) and competitive pressure in the tower REIT sector. Recent institutional selling and technical weakness indicate near-term caution despite long-term growth potential from wireless infrastructure demand.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
